Full Text Journal Articles by
Author Ulrich Beschorner

Advertisement

Find full text journal articles






Outcomes of directional atherectomy for common femoral artery disease.

Tanja Böhme, Leonardo Romano, Roland-Richard Macharzina, Elias Noory, Ulrich Beschorner, Börries Jacques, Karlheinz Bürgelin, Peter-Christian Flügel, Thomas Zeller, Aljoscha Rastan,

<h4>Background</h4>Endovascular therapy is the first-line strategy for femoropopliteal obstructive disease. However, for lesions involving the common femoral artery (CFA) surgical endarterectomy is still the gold standard.<h4>Aims</h4>The aim of this study was to evaluate the safety and efficacy of directional atherectomy (DA) for the treatment of CFA lesions.<h4>Methods</h4>A retrospective analysis of ... Read more >>

EuroIntervention (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology)
[2021, 17(3):260-266]

Cited: 0 times

View full text PDF listing >>



Atherectomy and Drug-Coated Balloon Angioplasty for the Treatment of Long Infrapopliteal Lesions: A Randomized Controlled Trial.

Aljoscha Rastan, Marianne Brodmann, Tanja Böhme, Roland Macharzina, Elias Noory, Ulrich Beschorner, Peter-Christian Flügel, Karlheinz Bürgelin, Franz-Josef Neumann, Thomas Zeller,

[Figure: see text]. ... Read more >>

Circ Cardiovasc Interv (Circulation. Cardiovascular interventions)
[2021, 14(6):e010280]

Cited: 0 times

View full text PDF listing >>



Advertisement

Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC).

Tanja Böhme, Elias Noory, Ulrich Beschorner, Frederik Lerke, Andrej Schmidt, Dierk Scheinert, Wulf Ito, Thomas Zeller, Aljoscha Rastan,

<i>Background:</i> To evaluate the safety and effectiveness of preparing instent femoropopliteal lesion with photoablative laser atherectomy or plain balloon angioplasty (POBA) prior to drug-coated balloon (DCB) angioplasty. <i>Patients and methods:</i> The prospective, multicenter, randomized study enrolled patients with Rutherford-Becker-class (RBC) 1 to 5 and instent lesions located in superficial femoral ... Read more >>

Vasa (VASA. Zeitschrift fur Gefasskrankheiten)
[2021, :1-7]

Cited: 0 times

View full text PDF listing >>



Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene - a single center experience.

Tanja Böhme, Elias Noory, Ulrich Beschorner, Börries Jacques, Karlheinz Bürgelin, Roland Macharzina, Lisa-Marie Kuhn, Thomas Nührenberg, Franz-Josef Neumann, Thomas Zeller,

<i>Background</i>: A recent meta-analysis of randomized controlled trials suggested an increased long-term mortality risk following femoropopliteal angioplasty using paclitaxel coated devices. To assess the long-term mortality after paclitaxel drug-coated (DCB) and uncoated balloon angioplasty (POBA) of femoropopliteal lesions in patients with ulcerations and gangrene in real world practice. <i>Patients and ... Read more >>

Vasa (VASA. Zeitschrift fur Gefasskrankheiten)
[2021, 50(2):132-138]

Cited: 1 time

View full text PDF listing >>



Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial.

Marc Bosiers, Koen Deloose, Joren Callaert, Jürgen Verbist, Jeroen Hendriks, Patrick Lauwers, Herman Schroë, Wouter Lansink, Dierk Scheinert, Andrej Schmidt, Thomas Zeller, Ulrich Beschorner, Elias Noory, Giovanni Torsello, Martin Austermann, Jeroen Wauters,

<h4>Background</h4>This clinical trial aims to evaluate the outcome (up to 24-months) of the treatment of in-stent restenotic or reoccluded lesions in the femoropopliteal arteries, by comparing the treatment of the GORE<sup>®</sup> VIABAHN<sup>®</sup> Endoprosthesis with PROPATEN Bioactive Surface (W. L. Gore & Associates, Flagstaff, AZ, USA) with a standard PTA treatment. ... Read more >>

J Cardiovasc Surg (Torino) (The Journal of cardiovascular surgery)
[2020, 61(5):617-625]

Cited: 1 time

View full text PDF listing >>



Provisional focal stenting of complex femoropopliteal lesions using the Multi-LOC multiple stent delivery system - 12-month results from the LOCOMOTIVE EXTENDED study.

Klaus Amendt, Thomas Zeller, Robert Proczka, Ulrich Beschorner, Nicola Troisi, Matthias Waliszewski, Ralf Langhoff, Hans Krankenberg, Andreas Hansch, Tomislav Krcmar, Vinko Vidjak, Claus Nolte-Ernsting, Alexander Hansen, Martin Sigl,

<i>Background</i>: This study aimed to evaluate a Multiple Stent Delivery System for provisional focal stenting of the femoropopliteal artery. <i>Patient and methods</i>: The LOCOMOTIVE EXTENDED study (Multi-<u>LOC</u> for fl<u>O</u>w li<u>M</u>iting <u>O</u>utcomes after plain old balloon angioplasty and/or drug-coated balloon <u>T</u>reatment in the infrainguinal position with the object<u>IVE</u> to implant multiple ... Read more >>

Vasa (VASA. Zeitschrift fur Gefasskrankheiten)
[2021, 50(3):209-216]

Cited: 0 times

View full text PDF listing >>



Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world.

Tanja Böhme, Elias Noory, Ulrich Beschorner, Börries Jacques, Karlheinz Bürgelin, Roland Macharzina, Thomas Nührenberg, Florian Cheung, Franz-Josef Neumann, Thomas Zeller,

<h4>Objectives</h4>To evaluate the long-term mortality after paclitaxel-coated drug-eluting stent (DES) angioplasty and use of uncoated devices of femoropopliteal lesions in real world practice.<h4>Background</h4>A meta-analysis of randomized controlled trials reported an increased risk of long-term mortality after femoropopliteal angioplasty with paclitaxel-coated devices.<h4>Methods</h4>Retrospective mortality analysis of claudicants Rutherford-Becker class (RBC) 1-4 who ... Read more >>

Catheter Cardiovasc Interv (Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions)
[2020, 96(6):1306-1314]

Cited: 1 time

View full text PDF listing >>



Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial.

Tanja Böhme, Elias Noory, Klaus Brechtel, Dierk Scheinert, Marc Bosiers, Ulrich Beschorner, Thomas Zeller,

<h4>Purpose</h4>To evaluate the 36-month technical and clinical outcome after implantation of the 25-cm Viabahn endoprosthesis with Propaten bioactive surface in TransAtlantic Inter-Society Consensus II C and D lesions of the superficial femoral and proximal popliteal arteries.<h4>Materials and methods</h4>This prospective, multicenter, single-arm trial (<i>ClinicalTrials.gov</i>; identifier NCT01263665) enrolled 71 patients (mean age ... Read more >>

J Endovasc Ther (Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists)
[2021, 28(2):222-228]

Cited: 0 times

View full text PDF listing >>



The SELUTION SLR™ drug-eluting balloon system for the treatment of symptomatic femoropopliteal lesions.

Tanja Böhme, Elias Noory, Ulrich Beschorner, Roland Macharzina, Thomas Zeller,

Endovascular treatment has become first line therapy for the treatment of femoropopliteal disease. Drug-coated devices play a key role in maintaining vessel patency. In the past antiproliferative coating of drug-coated balloons (DCBs) exclusively consisted of paclitaxel. Use of limus drugs was limited by a short residency time in the vessel ... Read more >>

Future Cardiol (Future cardiology)
[2021, 17(2):257-267]

Cited: 0 times

View full text PDF listing >>



Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial.

Ulf Teichgräber, Thomas Lehmann, René Aschenbach, Markus Thieme, Thomas Zeller, Ulrich Beschorner, Dierk Scheinert,

Radiology (Radiology)
[2020, 296(3):638-640]

Cited: 0 times

View full text PDF listing >>



Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.

Thomas Zeller, Klaus Brechtel, Dirk-Roelfs Meyer, Elias Noory, Ulrich Beschorner, Thomas Albrecht,

<b>Purpose:</b> To evaluate the safety and efficacy of the novel SELUTION sustained-limus-release (SLR) drug-eluting balloon (DEB) in the treatment of femoropopliteal lesions. <b>Materials and Methods:</b> Between October 2016 and May 2017, 50 subjects (mean age 69.6±10.4 years; 29 men) with symptomatic moderate to severe lower limb ischemia (Rutherford categories 2 ... Read more >>

J Endovasc Ther (Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists)
[2020, 27(5):683-690]

Cited: 1 time

View full text PDF listing >>



Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.

Tanja Böhme, Elias Noory, Ulrich Beschorner, Börries Jacques, Karlheinz Bürgelin, Roland Macharzina, Ellen Gebauer, Florian Cheung, Peter Lechner, Thomas Nührenberg, Thomas Zeller,

<h4>Objectives</h4>This study sought to evaluate the long-term mortality after paclitaxel drug-coated balloon (DCB) angioplasty and plain old balloon angioplasty (POBA) of femoropopliteal lesions in real-world practice.<h4>Background</h4>A recent meta-analysis of randomized controlled trials suggested an increased long-term mortality risk following femoropopliteal angioplasty using paclitaxel-coated devices.<h4>Methods</h4>A retrospective mortality analysis of patients with ... Read more >>

JACC Cardiovasc Interv (JACC. Cardiovascular interventions)
[2020, 13(17):2052-2061]

Cited: 4 times

View full text PDF listing >>



Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial.

Ulf Teichgräber, Thomas Lehmann, René Aschenbach, Dierk Scheinert, Thomas Zeller, Klaus Brechtel, Erwin Blessing, Michael Lichtenberg, Sebastian Sixt, Steffen Brucks, Ulrich Beschorner, Christof Tobias Klumb, Markus Thieme, ,

AIMS:Although paclitaxel drug-coated balloon (DCB) angioplasty is an established endovascular treatment for peripheral artery disease, restenosis remains a major concern. Thus, we compared a novel paclitaxel-coated DCB with nano-coating technology with uncoated plain old balloon angioplasty (POBA). METHODS AND RESULTS:This multicentre trial randomly assigned 171 patients with stenotic and occlusive ... Read more >>

EuroIntervention (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology)
[2020, 15(18):e1633-e1640]

Cited: 3 times

View full text PDF listing >>



Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial.

Ulf Teichgräber, Thomas Lehmann, René Aschenbach, Dierk Scheinert, Thomas Zeller, Klaus Brechtel, Erwin Blessing, Michael Lichtenberg, Peter von Flotow, Britta Heilmeier, Sebastian Sixt, Steffen Brucks, Christian Erbel, Ulrich Beschorner, Michael Werk, Vicenç Riambau, Andreas Wienke, Christof Tobias Klumb, Markus Thieme,

Background Paclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred treatment for revascularization of femoropopliteal lesions in peripheral artery disease, but mortality is a safety concern. Purpose To assess 2-year efficacy and safety of DCB angioplasty compared with conventional balloon angioplasty (also known as plain old balloon angioplasty or POBA). ... Read more >>

Radiology (Radiology)
[2020, 295(2):478-487]

Cited: 3 times

View full text PDF listing >>



Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic.

Thomas Zeller, Elias Noory, Ulrich Beschorner, Tanja Böhme, Michel Mpj Reijnen,

Vasa (VASA. Zeitschrift fur Gefasskrankheiten)
[2019, 48(2):109-111]

Cited: 0 times

View full text PDF listing >>



Focal Stenting of Complex Femoropopliteal Lesions with the Multi-LOC Multiple Stent Delivery System: 12-Month Results of the Multicenter LOCOMOTIVE Study.

Martin Sigl, Ulrich Beschorner, Thomas Zeller, Matthias Waliszewski, Ralf Langhoff, Jörg Tautenhahn, Klaus Amendt,

<h4>Introduction</h4>The purpose of this observational study is to report the 12-month clinical outcomes with the novel Multiple Stent Delivery System (MSDS) to treat complex femoropopliteal lesions. Previously, we reported the 6-month clinical outcomes of the all-comers LOCOMOTIVE study, which demonstrated the safety and efficacy of the MSDS with a favorable ... Read more >>

Cardiovasc Intervent Radiol (Cardiovascular and interventional radiology)
[2019, 42(2):169-175]

Cited: 1 time

View full text PDF listing >>



First clinical experience with the Multi-LOC multiple stent delivery system for focal stenting in long femoro-popliteal lesions.

Klaus Amendt, Ulrich Beschorner, Matthias Waliszewski, Martin Sigl, Ralf Langhoff, Jörg Thalwitzer, Ulf Redlich, Britta Vogel, Dirk Härtel, Thomas Zeller,

Background: The purpose of this observational study is to report the six-month clinical outcomes with a new multiple stent delivery system in patients with femoro-popliteal lesions. Patients and methods: The LOCOMOTIVE study is an observational multicentre study with a primary endpoint target lesion revascularization (TLR) rate at six months. Femoro-popliteal ... Read more >>

Vasa (VASA. Zeitschrift fur Gefasskrankheiten)
[2017, 46(6):452-461]

Cited: 1 time

View full text PDF listing >>



Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty.

Marc Bosiers, Dierk Scheinert, Jeroen M H Hendriks, Christian Wissgott, Patrick Peeters, Thomas Zeller, Marianne Brodmann, Robert Staffa, ,

<h4>Objective</h4>The mechanism of angioplasty is disruption of atherosclerotic plaque, which often results in dissections. Dissection after percutaneous transluminal angioplasty (PTA) remains a significant clinical problem and untreated may cause acute occlusion or later restenosis. Stents are used to manage dissections, which is often followed by in-stent restenosis and occasionally stent ... Read more >>

J Vasc Surg (Journal of vascular surgery)
[2016, 64(1):109-116]

Cited: 4 times

View full text PDF listing >>



Duplex derived intrarenal resistance index correlates with invasive pressure gradient measurements in detecting relevant unilateral renal artery stenosis.

Elias Noory, Aljoscha Rastan, Ulrich Beschorner, Roland Macharzina, Thomas Zeller,

<h4>Background</h4>The purpose of this study was to assess the correlation between the transstenotic pressure gradient as determined by a pressure wire and the decrease in the intrarenal resistance index (RI) > 0.05 measured by duplex ultrasound in significant unilateral renal artery stenosis (RAS). Intravascular ultrasound (IVUS) was correlated to the ... Read more >>

Vasa (VASA. Zeitschrift fur Gefasskrankheiten)
[2016, 45(2):175-180]

Cited: 2 times

View full text PDF listing >>



Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial.

Hans Krankenberg, Thilo Tübler, Maja Ingwersen, Michael Schlüter, Dierk Scheinert, Erwin Blessing, Sebastian Sixt, Arne Kieback, Ulrich Beschorner, Thomas Zeller,

<h4>Background</h4>Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis prevention for de novo superficial femoral artery disease. For in-stent restenosis, the benefit of DCBA over POBA remains uncertain.<h4>Methods and results</h4>One hundred nineteen patients with superficial femoral artery in-stent restenosis and chronic ... Read more >>

Circulation (Circulation)
[2015, 132(23):2230-2236]

Cited: 51 times

View full text PDF listing >>



Drug-Eluting Balloon Therapy for Femoropopliteal Occlusive Disease: Predictors of Outcome With a Special Emphasis on Calcium.

Gunnar Tepe, Ulrich Beschorner, Charlotte Ruether, Imma Fischer, Peter Pfaffinger, Elias Noory, Thomas Zeller,

<h4>Purpose</h4>To assess the association of patient, lesion, and procedure variables, including calcification, with late lumen loss (LLL) after use of drug-eluting balloon (DEB) therapy in patients with femoropopliteal arterial disease.<h4>Methods</h4>In this retrospective study, 91 patients (mean age 72.0±8.62 years; 50 men) were analyzed at 6 months after DEB treatment. Lesions ... Read more >>

J Endovasc Ther (Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists)
[2015, 22(5):727-733]

Cited: 23 times

View full text PDF listing >>



History of transient ischaemic attack, myocardial infarction and hyperlipidaemia affects outcome following carotid artery stenting.

Roland Richard Macharzina, Christian Claus, Steven R Messé, Tanja Boehme, Werner Vach, Thomas Winker, Aljoscha Rastan, Ulrich Beschorner, Elias Noory, Franz-Josef Neumann, Thomas Zeller,

<h4>Aims</h4>This prospective registry study was intended to evaluate outcomes and predictors of adverse events following carotid artery stenting (CAS).<h4>Methods and results</h4>Patients received neurological and duplex exams before CAS, prior to discharge and at 30- and 180-day follow-up. Multiple regression analysis included patient- and procedure-related characteristics. The MACCE endpoint comprised stroke, ... Read more >>

EuroIntervention (EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology)
[2015, 11(7):808-815]

Cited: 2 times

View full text PDF listing >>



Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries).

Thomas Zeller, Ulrich Beschorner, Ernst Pilger, Marc Bosiers, Koen Deloose, Patrick Peeters, Dierk Scheinert, Karl-Ludwig Schulte, Aljoscha Rastan, Marianne Brodmann,

<h4>Objectives</h4>The aim of BIOLUX P-II (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries) trial was to compare the safety and efficacy of a novel paclitaxel-coated drug-eluting balloon (DEB) versus an uncoated ... Read more >>

JACC Cardiovasc Interv (JACC. Cardiovascular interventions)
[2015, 8(12):1614-1622]

Cited: 44 times

View full text PDF listing >>



Novel Approaches to the Management of Advanced Peripheral Artery Disease: Perspectives on Drug-Coated Balloons, Drug-Eluting Stents, and Bioresorbable Scaffolds.

Thomas Zeller, Aljoscha Rastan, Roland Macharzina, Ulrich Beschorner, Elias Noory,

Introducing anti-restenotic drug-based treatment modalities in femoropopliteal interventions is the potential revolutionizing reperfusion treatment of peripheral artery disease. Durability of recanalization procedures using drug-coated balloons (DCB) and drug-eluting stents (DES) yields in excellent mid-term and long-term technical and clinical outcomes and may be cost saving on the long term as ... Read more >>

Curr Cardiol Rep (Current cardiology reports)
[2015, 17(9):624]

Cited: 3 times

View full text PDF listing >>



Drug-coated balloons: how should we incorporate into our practice in treating superficial femoral artery lesions?

Thomas Zeller, Aljoscha Rastan, Roland Macharzina, Ulrich Beschorner, Elias Noory,

<h4>Opinion statement</h4>Drug-coated balloons (DCBs) provide a novel method to locally deliver paclitaxel into the arterial wall without the need of a chronically implanted delivery system. Following the first positive pilot studies, two large pivotal trials have confirmed superiority of DCBs over plain old balloon angioplasty (POBA) in the treatment of ... Read more >>

Curr Treat Options Cardiovasc Med (Current treatment options in cardiovascular medicine)
[2015, 17(5):380]

Cited: 2 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2198 s